Poly Medicure Performance
- Today's Low
- ₹1,390
- Today's High
- ₹1,467
- 52 Week Low
- ₹1,182
- 52 Week High
- ₹2,317
- Open Price₹1,390
- Previous Close₹1,383
- Volume300,893
- 50 DMA₹1,454.42
- 100 DMA₹1,505.61
- 200 DMA₹1,653.78
Poly Medicure Chart
Investment Returns
- Over 1 Month -11.7%
- Over 3 Month + 7.57%
- Over 6 Month -21.49%
- Over 1 Year -34.67%
Smart Investing Starts Here Start SIP with Poly Medicure for Steady Growth!
Poly Medicure Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 45.9
- PEG Ratio
- -9.5
- Market Cap Cr
- 14,786
- P/B Ratio
- 4.9
- Average True Range
- 68.54
- EPS
- 32.29
- Dividend Yield
- 0.2
- MACD Signal
- -22.22
- RSI
- 43.77
- MFI
- 36.74
Latest Stock News Updates
Healthcare Supplies company Poly Medicure announced Q4FY26 & FY26 results Consolidated Financial Highlights: Revenue from Operations: For Q4FY26, Revenue from Operations stood at Rs 53,451.14 lakh, registering a growth of 8.28% QoQ compared to Rs 49,365.55 lakh in Q3FY26, and a strong increase of 21.25% YoY from Rs 44,082.82 lakh in Q4FY25. Annual Revenue from Operations: For the full year FY26, Revenue from Operations amounted to Rs 1,87,525.92 lakh, reflecting a 12.30% YoY growth from Rs 1,66,983.16 lakh in FY25. Total Income: In Q4FY26, Total Income reached Rs 55,226.79 lakh, up by 6.22% QoQ from Rs 51,991.89 lakh in Q3FY26, and higher by 18.73% YoY compared to Rs 46,513.77 lakh in Q4FY25. Annual Total Income: For FY26, Total Income stood at Rs 1,99,534.14 lakh, an increase of 13.44% YoY against Rs 1,75,895.92 lakh in FY25. Net Profit: Net Profit for Q4FY26 was reported at Rs 6,504.10 lakh, reflecting a decline of 8.15% QoQ from Rs 7,080.89 lakh in Q3FY26, and a decrease of 29.18% YoY from Rs 9,183.42 lakh in Q4FY25. Annual Net Profit: For FY26, Net Profit stood at Rs 32,072.99 lakh, a slight drop of 5.27% YoY compared to Rs 33,855.72 lakh in FY25. Total Comprehensive Income: Total Comprehensive Income for Q4FY26 was Rs 8,993.90 lakh, and for the full year FY26, it amounted to Rs 36,721.58 lakh. Standalone Financial Highlights: Revenue from Operations: Revenue from Operations for Q4FY26 came in at Rs 44,301.49 lakh, up by 5.77% QoQ from Rs 41,886.15 lakh in Q3FY26, and growing by 5.24% YoY from Rs 42,096.94 lakh in Q4FY25. Annual Revenue from Operations: For FY26, Annual Revenue from Operations was Rs 1,66,246.48 lakh, showing an increase of 3.79% YoY against Rs 1,60,179.98 lakh in FY25. Total Income: Total Income for Q4FY26 was Rs 45,813.68 lakh, registering an increase of 2.17% QoQ against Rs 44,841.37 lakh in Q3FY26, and a 2.97% growth YoY from Rs 44,491.80 lakh in Q4FY25. Annual Total Income: For FY26, Annual Total Income stood at Rs 1,78,238.25 lakh, growing 5.37% YoY from Rs 1,69,157.22 lakh in FY25. Net Profit: Net Profit for Q4FY26 was Rs 8,062.17 lakh, increasing by 2.86% QoQ from Rs 7,838.38 lakh in Q3FY26, but declining by 6.97% YoY from Rs 8,666.02 lakh in Q4FY25. Annual Net Profit: For FY26, Net Profit was Rs 33,598.49 lakh, reflecting a marginal growth of 1.40% YoY from Rs 33,133.47 lakh in FY25. Total Comprehensive Income: Total Comprehensive Income for Q4FY26 was Rs 8,125.00 lakh, and for the full year FY26, it stood at Rs 33,621.11 lakh. Business & Segment Highlights: Dividend: The Board of Directors recommended a dividend of Rs 3.50 (70%) per Equity Share of Rs 5 each for the financial year 2025-26, subject to the approval of shareholders. Segment Performance: The company's operations fall entirely under "Medical Devices", which is considered to be the only reportable segment by the management. Therefore, overall financial results fully reflect the performance of this single segment. Fund Raising (QIP): The company successfully raised Rs 99,999.98 lakh during the previous year by issuing 53,19,148 equity shares of Rs 5 each at a premium of Rs 1,875 each (issue price of Rs 1,880 per share) to Qualified Institutional Investors on a QIP basis. Strategic Acquisitions: The Group acquired 90% economic rights in the Pendracare Group (comprising Pendracare Holdings BV and Welling Medical BV) through RISOR Holding BV. The Group also acquired 100% economic rights in Medistream SA, Switzerland (comprising Citieffe group) through its wholly owned subsidiary company Poly Medicure BV Netherlands. Resolution Plan Approval: The Hon’ble NCLT of Allahabad approved the company's resolution plan for Himalayan Mineral Water Private Limited (Target Company). An amount of Rs 3,316.00 lakh has been deposited to acquire 100% equity shareholding in the target company. Auditor Appointments: The company approved the re-appointment of M/s. PricewaterhouseCoopers Services LLP and M/s Oswal Sunil & Co. (Chartered Accountants) as Internal Auditors for FY27. Result PDF
- Trendlyne
- 2 weeks ago
Healthcare Supplies company Poly Medicure announced Q3FY26 results Revenue: Rs 493.7 crore against Rs 424.2 crore during Q3FY25, change 16%. EBITDA: Rs 119.4 crore against Rs 116.1 crore during Q3FY25, change 3%. EBITDA Margin: 24.2% for Q3FY26. PBT: Rs 97.6 crore against Rs 113.2 crore during Q3FY25, change -14%. PAT: Rs 70.8 crore against Rs 85.2 crore during Q3FY25, change -17%. PAT Margin: 13.6% for Q3FY26. EPS: Rs 7 for Q3FY26. Result PDF
- Trendlyne
- 4 months ago
Conference Call with Poly Medicure Management and Analysts on Q2FY26 Performance and Outlook. Listen to the full earnings transcript.
- Trendlyne
- 6 months 4 weeks ago
Poly Medicure Financials
Poly Medicure Technicals
EMA & SMA
- Bearish Moving Average 6
- Bullish Moving Average 10
- 20 Day
- ₹1,436.44
- 50 Day
- ₹1,454.42
- 100 Day
- ₹1,505.61
- 200 Day
- ₹1,653.78
Resistance and Support
- R3 1,479.43
- R2 1,455.27
- R1 1,419.03
- S1 1,358.63
- S2 1,334.47
- S3 1,298.23
Poly Medicure Corporate Actions - Bonus, Splits, Dividends
About Poly Medicure
- NSE Symbol
- POLYMED
- BSE Symbol
- 531768
- Managing Director
- Mr. Himanshu Baid
- ISIN
- INE205C01021
Similar Stocks to Poly Medicure
Popular Stocks
Poly Medicure FAQs
Poly Medicure share price is ₹1,458 As on 09 June, 2026 | 16:24
The Market Cap of Poly Medicure is ₹14786.3 Cr As on 09 June, 2026 | 16:24
The P/E ratio of Poly Medicure is 45.9 As on 09 June, 2026 | 16:24
The PB ratio of Poly Medicure is 4.9 As on 09 June, 2026 | 16:24
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.